Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | -122.15K | 89.35% |
| Net profit | -7.82M | 70.77% |
| EBITDA | -6.22M | 65.03% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.01M |
Number of shares | 3.78M |
52-week high/low | €0.37 - €0.27 |
| Dividends | No |
Beta | 2.44 |
P/E ratio | -0.02 |
PEG ratio | 0.00 |
P/B ratio | 0.02 |
P/S ratio | 0.00 |
Company profile
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Name | Altamira Therapeutics Aktie |
| CEO | Thomas Meyer |
| Headquarters | Hamilton,
Bermuda |
| Website | |
| Industry | Chemicals |
| IPO | 08/06/2014 |
| Employees | 10 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CYTO |
